Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up—a case–control study
2018
Purpose
Breast cancer is the leading cause of death from cancer in women and the most common cancer in the world [1]. To date, many patients with estrogen-receptor-positive (ER+) breast cancer are overtreated with chemotherapy when the rationale for adjuvant chemotherapy is based on clinicopathologic parameters. Different studies were able to demonstrate that a 21-gene expression assay (Oncotype DX® Genomic Health, Redwood City, CA) can predict the benefit from adjuvant chemotherapy in ER+ breast cancers [2, 3] and provide additional prognostic information independent of clinicopathological features [4].
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
5
Citations
NaN
KQI